Turning Point Therapeutics, Inc.

NasdaqGS:TPTX Rapporto sulle azioni

Cap. di mercato: US$3.8b

Turning Point Therapeutics Gestione

Gestione criteri di controllo 1/4

Turning Point Therapeutics Il CEO è Athena Countouriotis, nominato in Sep2018, e ha un mandato di 3.92 anni. la retribuzione annua totale è $ 16.94M, composta da 3.8% di stipendio e 96.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.22% delle azioni della società, per un valore di $ 8.39M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 2 anni.

Informazioni chiave

Athena Countouriotis

Amministratore delegato

US$16.9m

Compenso totale

Percentuale dello stipendio del CEO3.8%
Mandato del CEO3.9yrs
Proprietà del CEO0.2%
Durata media del management2.3yrs
Durata media del Consiglio di amministrazione2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Jul 21

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Mar 23
We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

Dec 06
Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

The Take On Turning Point Therapeutics

Dec 03

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Aug 15
Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Aug 04
Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Jun 17

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 08
Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Feb 26
Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Jan 29

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Jan 22
Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

Jan 13
We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers

Dec 28

Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

Dec 15
Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer

Dec 08

Turning Point Therapeutics EPS beats by $0.12, beats on revenue

Nov 12

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Athena Countouriotis rispetto agli utili di Turning Point Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2022n/an/a

-US$342m

Mar 31 2022n/an/a

-US$275m

Dec 31 2021US$17mUS$651k

-US$237m

Sep 30 2021n/an/a

-US$205m

Jun 30 2021n/an/a

-US$157m

Mar 31 2021n/an/a

-US$132m

Dec 31 2020US$15mUS$580k

-US$157m

Sep 30 2020n/an/a

-US$131m

Jun 30 2020n/an/a

-US$134m

Mar 31 2020n/an/a

-US$119m

Dec 31 2019US$3mUS$544k

-US$72m

Sep 30 2019n/an/a

-US$60m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$34m

Dec 31 2018US$9mUS$329k

-US$25m

Compensazione vs Mercato: La retribuzione totale di Athena ($USD 16.94M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.60M ).

Compensazione vs guadagni: La retribuzione di Athena è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Athena Countouriotis (50 yo)

3.9yrs

Mandato

US$16,940,858

Compensazione

Dr. Athena Maria Countouriotis, M.D. is Chief Executive Officer and Director at Turning Point Therapeutics, Inc. since September 2018. She has been Independent Director of Passage Bio, Inc since February 2...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Athena Countouriotis
President3.9yrsUS$16.94m0.22%
$ 8.4m
Paolo Tombesi
Executive VP & CFO1.1yrsUS$4.58m0.057%
$ 2.2m
Mohammad Hirmand
Executive VP & Chief Medical Officer2.7yrsUS$5.61m0.082%
$ 3.1m
Ed Gemo
Senior VP & Chief Information Officerno dataNessun datoNessun dato
Gavin Hirst
Senior VP of Chemistry & Interim Chief Scientific Officerno dataNessun datoNessun dato
Adam Levy
Senior Vice President of Investor Relations & Corporate Communicationsless than a yearNessun datoNessun dato
Raymond Furey
Senior VP & Chief Compliance Officerno dataNessun datoNessun dato
Brian Sun
Senior VPless than a yearNessun datoNessun dato
Heather Adams
Senior Vice President of Human Resources2.1yrsNessun datoNessun dato
Jeffrey Whitten
Senior Vice President of Pre-Clinical Developmentno dataNessun datoNessun dato
Xiaohua Xin
Senior Vice President of Clinical Development3.6yrsNessun datoNessun dato
Homa Yeganegi
Senior VP2.6yrsNessun datoNessun dato

2.3yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di TPTX è considerato esperto (durata media dell'incarico 2.3 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Athena Countouriotis
President3.9yrsUS$16.94m0.22%
$ 8.4m
Kevan Shokat
Chairman of Scientific Advisory Board2yrsNessun datoNessun dato
C. Machado
Independent Director3.3yrsUS$424.79k0%
$ 0
Carol Gallagher
Independent Director3.1yrsUS$415.29k0%
$ 0
Benjamin Cravatt
Member of Scientific Advisory Board2yrsNessun dato0%
$ 0
Garry Nicholson
Independent Director2.6yrsUS$422.74k0%
$ 0
Simeon George
Independent Non-Executive Director5.3yrsUS$414.41k0%
$ 0
Mark J. Alles
Independent Chairman of the Board1.3yrsUS$861.18k0.0040%
$ 151.9k
Barbara Bodem
Independent Director1.4yrsUS$1.00mNessun dato
Daniel Von Hoff
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Natalia Jura
Member of the Scientific Advisory Board2yrsNessun datoNessun dato
Michael Varney
Member of the Scientific Advisory Board2yrsNessun datoNessun dato

2.0yrs

Durata media

55.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di TPTX non è considerato esperto (durata media del mandato 2 anni), il che suggerisce un nuovo consiglio.